3569-33-3

Basic information

• Product Name: 2-CHLORO-N,6-DIMETHYL-4-PYRIMIDINAMINE
• Synonyms: 2-CHLORO-N,6-DIMETHYL-4-PYRIMIDINAMINE;2-chloro-N,6-dimethyl-4-pyrimidinamine(SALTDATA: FREE)
• CAS NO: 3569-33-3
• Molecular Formula: C6H8ClN3
• Molecular Weight: 157.6
• Mol File: 3569-33-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 304°C at 760 mmHg
• Flash Point: 137.7°C
• Appearance: /
• Density: 1.275g/cm³
• Vapor Pressure: 0.000899mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-CHLORO-N,6-DIMETHYL-4-PYRIMIDINAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N,6-DIMETHYL-4-PYRIMIDINAMINE(3569-33-3)
• EPA Substance Registry System: 2-CHLORO-N,6-DIMETHYL-4-PYRIMIDINAMINE(3569-33-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 3569-33-3(Hazardous Substances Data)

Usage

General Description

2-Chloro-N,6-Dimethyl-4-Pyrimidinamine, also known as CDMP, is a chemical compound with the molecular formula C6H9ClN4. It is a derivative of pyrimidine and is categorized as an organochlorine compound. Its primary use is in the synthesis of other chemical products. It appears as an off-white to light yellowish powder. The Chloro Pyrimidinamine exhibits typical properties of amines and chlorides; therefore, it has a high reactivity with oxidizing agents, acids, and halogens. Also, it should be noted that appropriate safety measures should be exercised in handling this compound as it can cause harm to the eyes, skin, and if inhaled or ingested.

InChI:InChI=1/C6H8ClN3/c1-4-3-5(8-2)10-6(7)9-4/h3H,1-2H3,(H,8,9,10)

Upstream product

• 5424-21-5 2,4-dichloro-6-methylpyrimidine 
• 74-89-5 methylamine 
• 626-48-2 2,4-dihydroxy-6-methylpyrimidine 
• 593-51-1 methylamine hydrochloride 

Relevant articles and documents

Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer

5-Fluorouracil (5-FU) and its prodrugs are the essential clinical drugs for colorectal cancer (CRC) treatment. However, the drug resistance of 5-FU has caused high mortality of CRC patients. Thus, it is urgent to develop reversal agents of 5-FU resistance. Sphingosine-1-phosphate receptor 2 (S1PR2) was proved to be a potential target for reversing 5-FU resistance, but the activity of known S1PR2 antagonists JTE-013 were weak in 5-FU-resistant cell lines. To develop more potent S1PR2 antagonists to treat 5-FU-resistant cancer, a series of JTE-013 derivatives were designed and synthesized. The most promising compound 40 could markedly reverse the resistance in 5-FU-resistant HCT116 cells and 5-FU-resistant SW620 cells via inhibiting the expression of dihydropyrimidine dehydrogenase (DPD). The key was that compound 40 with improved pharmacokinetic properties significantly increased the inhibitory rate of 5-FU in the SW620/5-FU cells xenograft model with no observable toxicity by inhibiting the expression of DPD in tumor and liver tissues. Altogether, these results suggest that compound 40 may be a promising drug candidate to reverse 5-FU resistance in the treatment of CRC.

Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines

The discovery and optimization of a novel series of G9a/GLP (EHMT2/1) inhibitors are described. Starting from known G9a/GLP inhibitor 5, efforts to explore the structure-activity relationship and optimize drug properties led to a novel compound 13, the side chain of which was converted to tetrahydroazepine. Compound 13 showed increased G9a/GLP inhibitory activity compared with compound 5. In addition, compound 13 exhibited improved human ether-a-go-go related gene (hERG) inhibitory activity over compound 5 and also improved pharmacokinetic profile in mice (oral bioavailability: 17 to 40percent). Finally, the co-crystal structure of G9a in complex with compound 13 provides the basis for the further development of tetrahydroazepine-based G9a/GLP inhibitors.

AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF

The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) by administering an amine-substituted heterocyclic heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.